A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide

Journal of Immunology

Volumn 191, Issue 10, 2013, Pages 4969-4978

  Luo, Qiong ^a   Sun, Yang ^a   Liu, Wen ^a   Qian, Cheng ^a   Jin, Biao ^a   Tao, Feifei ^a   Gu, Yanhong ^b   Wu, Xingxin ^a,c   Shen, Yan ^a   Xu, Qiang ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; I KAPPA B KINASE; IGURATIMOD; INTERLEUKIN 17; LEFLUNOMIDE; MESSENGER RNA; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN ACT1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CHROMONE DERIVATIVE; CHUK PROTEIN, MOUSE; COLLAGEN; ISOXAZOLE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULFONAMIDE; TRAF3IP2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RESPONSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROBLAST; IN VIVO STUDY; LOSS OF APPETITE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA STABILITY; SIGNAL TRANSDUCTION; SYNOVIOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMPARATIVE STUDY; DBA MOUSE; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PHOSPHORYLATION; SYNOVIUM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CHROMONES; COLLAGEN; I-KAPPA B KINASE; INFLAMMATION; INTERLEUKIN-17; ISOXAZOLES; MALE; METHOTREXATE; MICE; MICE, INBRED DBA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SULFONAMIDES; SYNOVIAL MEMBRANE; TNF RECEPTOR-ASSOCIATED FACTOR 5;

EID: 84887473612     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300832     Document Type: Article

References (48)

1. McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7:429-442.
2. Smolen, J. S., and G. Steiner. 2003. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2:473-488.
3. McInnes, I. B., and G. Schett. 2011. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365:2205-2219.
4. Lanchbury, J. S. 1993. Genetic aspects of rheumatoid arthritis. Clin. Exp. Rheumatol. 11 (Suppl. 8):S9-S11.
5. Winchester, R. J. 1981. Genetic aspects of rheumatoid arthritis. Springer Semin. Immunopathol. 4:89-102.
6. Hyrich, K. L., and R. D. Inman. 2001. Infectious agents in chronic rheumatic diseases. Curr. Opin. Rheumatol. 13:300-304.
7. Chan, B. Y., M. M. Huang, M. Francesco, J. Chen, J. Sokolove, P. Magadala, W. H. Robinson, and J. J. Buggy. 2011. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 13:R115.
8. Zwerina, J., K. Redlich, G. Schett, and J. S. Smolen. 2005. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann. N. Y. Acad. Sci. 1051:716-729.
9. Vergunst, C. E., M. G. Van De Sande, M. C. Lebre, and P. P. Tak. 2005. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand. J. Rheumatol. 34:415-425.
10. Sweeney, S. E., and G. S. Firestein. 2004. Rheumatoid arthritis: regulation of synovial inflammation. Int. J. Biochem. Cell Biol. 36:372-378.
11. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423:356-361.
12. Gravallese, E. M. 2002. Bone destruction in arthritis. Ann. Rheum. Dis. 61(Suppl. 2):ii84-ii86.
13. Hirota, K., M. Hashimoto, H. Yoshitomi, S. Tanaka, T. Nomura, T. Yamaguchi, Y. Iwakura, N. Sakaguchi, and S. Sakaguchi. 2007. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J. Exp. Med. 204:41-47.
14. Gaffen, S. L. 2009. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr. Rheumatol. Rep. 11:365-370.
15. Aggarwal, S., and A. L. Gurney. 2002. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 71:1-8.
16. Kolls, J. K., and A. Lindén. 2004. Interleukin-17 family members and inflammation. Immunity 21:467-476.
17. Ouyang, W., J. K. Kolls, and Y. Zheng. 2008. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28:454-467.
18. Chang, S. H., and C. Dong. 2011. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell. Signal. 23:1069-1075.
19. Noss, E. H., and M. B. Brenner. 2008. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol. Rev. 223:252-270.
20. Mor, A., S. B. Abramson, and M. H. Pillinger. 2005. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin. Immunol. 115:118-128.
21. Abbott, J. D., and L. W. Moreland. 2004. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin. Investig. Drugs 13:1007-1018.
22. O'Dell, J. R. 2004. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350:2591-2602.
23. Nam, J. L., K. L. Winthrop, R. F. Van Vollenhoven, K. Pavelka, G. Valesini, E. M. Hensor, G. Worthy, R. Landewé, J. S. Smolen, P. Emery, and M. H. Buch. 2010. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 69:976-986.
24. Smolen, J. S., D. Aletaha, M. Koeller, M. H. Weisman, and P. Emery. 2007. New therapies for treatment of rheumatoid arthritis. Lancet 370:1861-1874.
25. Bathon, J. M., R. W. Martin, R. M. Fleischmann, J. R. Tesser, M. H. Schiff, E. C. Keystone, M. C. Genovese, M. C. Wasko, L. W. Moreland, A. L. Weaver, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343:1586-1593.
26. Weinblatt, M. E. 1995. Efficacy of methotrexate in rheumatoid arthritis. Br. J. Rheumatol. 34 (Suppl. 2):43-48.
27. Pincus, T., Y. Yazici, T. Sokka, D. Aletaha, and J. S. Smolen. 2003. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol. 21 (5, Suppl. 31) S179-S185.
28. Smolen, J. S., J. R. Kalden, D. L. Scott, B. Rozman, T. K. Kvien, A. Larsen, I. Loew-Friedrich, C. Oed, and R. Rosenburg; European Leflunomide Study Group. 1999. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353:259-266.
29. Breedveld, F. C., and J. M. Dayer. 2000. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59:841-849.
30. Elkayam, O., I. Yaron, I. Shirazi, R. Judovitch, D. Caspi, and M. Yaron. 2003. Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann. Rheum. Dis. 62:440-443.
31. Coulthard, L. G., J. Costello, B. Robinson, I. A. Shiels, S. M. Taylor, and T. M. Woodruff. 2011. Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigeninduced arthritis. Arthritis Res. Ther. 13:R42.
32. Du, F., L. J. Lü, Q. Fu, M. Dai, J. L. Teng, W. Fan, S. L. Chen, P. Ye, N. Shen, X. F. Huang, et al. 2008. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res. Ther. 10:R136.
33. Inaba, T., K. Tanaka, R. Takeno, H. Nagaki, C. Yoshida, and S. Takano. 2000. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6- phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models. Chem. Pharm. Bull. (Tokyo) 48:131-139.
34. Tanaka, K., T. Yamamoto, Y. Aikawa, K. Kizawa, K. Muramoto, H. Matsuno, and A. Muraguchi. 2003. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford) 42:1365-1371.
35. Jönsson, B., G. Kobelt, and J. Smolen. 2008. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur. J. Health Econ. 8 (Suppl. 2):S61-S86.
36. Cai, X., H. Zhou, Y. F. Wong, Y. Xie, Z. Q. Liu, Z. H. Jiang, Z. X. Bian, H. X. Xu, and L. Liu. 2007. Suppression of the onset and progression of collagen-induced arthritis in rats by QFGJS, a preparation from an anti-arthritic Chinese herbal formula. J. Ethnopharmacol. 110:39-48.
37. Kremer, J. M. 1999. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 29:14-26.
38. Holmdahl, R., R. Bockermann, J. Bäcklund, and H. Yamada. 2002. The molecular pathogenesis of collagen-induced arthritis in mice-a model for rheumatoid arthritis. Ageing Res. Rev. 1:135-147.
39. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171:6173-6177.
40. Nistala, K., H. Moncrieffe, K. R. Newton, H. Varsani, P. Hunter, and L. R. Wedderburn. 2008. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 58:875-887.
41. Pisitkun, P., E. Claudio, N. Ren, H. Wang, and U. Siebenlist. 2010. The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody. Arthritis Rheum. 62:3334-3344.
42. Wen, T., Y. Li, M. Wu, X. Sun, X. Bao, Y. Lin, J. Hao, L. Han, G. Cao, Z. Wang, et al. 2012. Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor a production and Th17 cell differentiation. Arthritis Rheum. 64:2896-2906.
43. Corrigall, V. M., E. Solau-Gervais, and G. S. Panayi. 2000. Lack of CD80 expression by fibroblast-like synoviocytes leading to anergy in T lymphocytes. Arthritis Rheum. 43:1606-1615.
44. Zhou, T., L. Ding, X. Li, F. Zhang, Q. Zhang, B. Gong, and X. Guo. 2008. Determination of iguratimod in rat plasma by high performance liquid chromatography: method and application. Biomed. Chromatogr. 22:260-264.
45. Hartupee, J., C. Liu, M. Novotny, X. Li, and T. Hamilton. 2007. IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 179:4135-4141.
46. May, M. J. 2011. IL-17R signaling: new players get in on the Act1. Nat. Immunol. 12:813-815.
47. Bulek, K., C. Liu, S. Swaidani, L. Wang, R. C. Page, M. F. Gulen, T. Herjan, A. Abbadi, W. Qian, D. Sun, et al. 2011. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat. Immunol. 12:844-852.
48. Sun, D., M. Novotny, K. Bulek, C. Liu, X. Li, and T. Hamilton. 2011. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat. Immunol. 12:853-860.